This article is more than 5 years old. Information may no longer be current.

Ista Pharmaceuticals to discontinue twice-daily bromfenac in favor of once-daily formulation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Ista Pharmaceuticals has announced plans to discontinue all shipments of twice-daily bromfenac ophthalmic solution 0.09% on February 28.

The announcement follows the rapid adoption of once-daily Bromday (bromfenac ophthalmic solution 0.09%) as the most popular name-brand ocular NSAID in the U.S. for reducing inflammation and pain after cataract surgery. The once-daily bromfenac formulation was approved by the U.S. Food and Drug Administration in October and has been granted 3 years of marketing exclusivity under the Drug Price Competition and Patent Term Restoration Act, according to a press release from Ista.

While Ista will stop supplying twice-daily Xibrom (bromfenac ophthalmic solution 0.09%) to wholesalers at the end of this month, the company expects a limited supply of the compound to be available for approximately 2 to 3 weeks thereafter.

"The transition to [Bromday] has been swift. As of the last week in January, 46% of the Xibrom new prescriptions have been converted over to [Bromday], according to weekly prescription data supplied by IMS," Vicente Anido Jr., PhD, president and CEO of Ista, said in the release. "We look forward to gaining even wider acceptance of Bromday throughout the prescribing ophthalmic community in the years to come."